Aerovate Therapeutics Inc
NASDAQ:AVTE
Intrinsic Value
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of AVTE.
Aerovate Therapeutics Inc's market capitalization is 598.8m USD.
AVTE stock price is 21.57 USD.
AVTE.
AVTE. Open DCF Valuation
AVTE. Open Relative Valuation
AVTE has upside potential of 111% compared to the average analyst price target.
Open Wall St Estimates
AVTE has negative Free Cash Flow for the last twelve months.
AVTE has negative Operating Income for the last twelve months.
AVTE has negative Net Income for the last twelve months.
AVTE's ROE (Return on Equity) has significantly increased in the last 3 years from -136% to -64%, and is approaching profitability.
AVTE's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 3 640% to -2 678%.
AVTE's ROE (Return on Equity) for the past 12 months is negative and is equal to -64%.
AVTE's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -2 678%.
AVTE has negative three-year average ROE (Return on Equity): -40%. The company is not efficient at transforming stockholders' equity into net income.
AVTE has negative three-year average ROIC (Return on Invested Capital): -3 142%. The company is not efficient at using invested capital to generate operating income.
AVTE's short-term assets (124m USD) exceed its short-term liabilties (18m USD).
AVTE's long-term assets (127m USD) exceed its long-term liabilties (18m USD).
AVTE's D/E (Debt to Equity) is very low and is equal to 0.
AVTE's Altman Z-Score is very high and is equal to 16.93.
Fundamental Analysis
Aerovate Therapeutics Inc
Balance Sheet Decomposition
Aerovate Therapeutics Inc
| Current Assets | 124.2m |
| Cash & Short-Term Investments | 122.4m |
| Other Current Assets | 1.8m |
| Non-Current Assets | 3.2m |
| PP&E | 902k |
| Other Non-Current Assets | 2.3m |
| Current Liabilities | 17.6m |
| Accounts Payable | 2.4m |
| Accrued Liabilities | 14.1m |
| Other Current Liabilities | 1.2m |
| Non-Current Liabilities | 325k |
| Other Non-Current Liabilities | 325k |
Earnings Waterfall
Aerovate Therapeutics Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-81.4m
USD
|
|
Operating Income
|
-81.4m
USD
|
|
Other Expenses
|
5.9m
USD
|
|
Net Income
|
-75.5m
USD
|
Free Cash Flow Analysis
Aerovate Therapeutics Inc
AVTE Profitability Score
Profitability Due Diligence
Aerovate Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Aerovate Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
AVTE Solvency Score
Solvency Due Diligence
Aerovate Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Aerovate Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AVTE Price Targets Summary
Aerovate Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
AVTE
is 45.56 USD
with a low forecast of 27.27 USD and a high forecast of 68.25 USD.
Ownership
AVTE Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
AVTE Price
Aerovate Therapeutics Inc
| Average Annual Return | 47.59% |
| Standard Deviation of Annual Returns | 141.01% |
| Max Drawdown | -64% |
| Market Capitalization | 598.8m USD |
| Shares Outstanding | 27 695 184 |
| Percentage of Shares Shorted | 6.27% |
Company Profile
Aerovate Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Boston, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The firm's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The firm has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. The company anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.
You don't have any saved screeners yet
